ClinicalTrials.gg
CompletedNCT04246762Updated Aug 15, 2024Results posted

Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

A Phase 1 interventional study of Olokizumab and Omeprazole in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
10th of 10
17 · median 206
Started
2021
the only one that year
Phase 1
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
5 of 10
R-Pharm International, LLC

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is the only one that started in 2021, is the only one in phase 1, and was the 10th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.

The goal of the study was to assess the effect of OKZ on the pharmacokinetics (PK) of the CYP450 probe substrates, caffeine (CYP1A2), S-warfarin (CYP2C9), omeprazole (CYP2C19), and midazolam (CYP3A4) in subjects with rheumatoid arthritis (RA).

Read the detailed description

This was a Phase 1, open-label, 3-period, single-sequence, crossover study in subjects with RA with increased C-reactive protein (CRP).

Approximately 15 eligible subjects were planned to be enrolled at approximately 3 study centers to have at least 12 evaluable subjects completing the study. However, if necessary, additional subjects could be dosed to obtain the 12 evaluable subjects required.

There was a 35-day Screening Period, followed by a 29-day study duration: eligible patients were administered a cocktail of 4 substrates alone with following 7 days PK-sampling (Period 1); a single subcutaneous dose of 128 mg OKZ was administered (Period 2) approximately 2 weeks prior to the second administration of the cocktail with following 7-days PK-sampling (Period 3). After completion of the Period 3 patients were followed-up for 19 weeks (133 days) for safety evaluations.

Overall duration of the study was approximately 200 days (6 and a half months).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • moderate Rheumatoid Arthritis
  • severe Rheumatoid Arthritis
  • subcutaneous
  • Olokizumab
  • drug interaction
  • CYP450
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects willing and able to give voluntary and sign an Informed Consent Form (ICF)
  2. Male subjects and their female partners and female subjects of must agree to adhere to the requirements for the study

    Female subjects of non-childbearing potential must be:

    • Surgically sterile (i.e. bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to first dosing), or
    • Naturally (spontaneous cessation of menses) for at least 24 consecutive months prior to first dosing, with a follicle stimulating hormone level at screening of ≥40 mIU/mL.
  3. of 18 kg/m2 to 29.9 kg/m2, inclusive, and body weight of 55 kg to 110 kg, inclusive, if male, and 45 kg to 100 kg, inclusive, if female.
  4. Subjects must have a diagnosis of adult onset RA classified by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 revised classification criteria for RA (Aletaha et al, 2010) for at least 12 weeks prior to Screening. If the subject was previously diagnosed according to ACR 1987 criteria, the Investigator may classify the subject per ACR 2010 retrospectively, based on medical history, and using available source data.
  5. Subjects must have received Methotrexate (MTX), sulfasalazine, or hydroxychloroquine for at least 12 weeks prior to Day 1 and in stable dose for at least 6 weeks prior to Day 1 without significant Adverse events (AEs). Stable doses of MTX should be 10 mg to 25 mg weekly with folic acid (at least 5 mg weekly or equivalent). No significant side effects based on the Investigator's judgment should be observed during treatment by these agents. The maximum allowed doses of sulfasalazine and hydroxychloroquine are:

    1. Sulfasalazine: 3 g per day
    2. Hydroxychloroquine: 400 mg per day

    Note: The doses should remain stable and not be changed from the time of signing the ICF until the end of the treatment period (EOT, Day 29).

  6. Subjects must have an increased CRP at Screening (of ≥1.2 × ).
  7. Female subjects of childbearing potential must have negative pregnancy test at Screening and throughout the study until the end of study (EOS) (Day 161).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of any other inflammatory arthritis or systemic inflammatory disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). Osteoarthritis is classified as a degenerative disease rather than an inflammatory disease.
  2. Subjects with Steinbrocker Class III or IV functional capacity (incapacitated, largely, or wholly bed ridden, or confined to a wheelchair, with little, or no self-care).
  3. Prior exposure to any licensed or compound directly or indirectly targeting IL-6 or IL-6R within 12 months of Day 1.
  4. Treatment with DMARDs other than MTX, hydroxychloroquine, or sulfasalazine. Treatment with the following DMARDs are not allowed within the specified time period prior to Day 1:

    1. 4 weeks for azathioprine, cyclosporine, chloroquine, gold, penicillamine, minocycline, or doxycycline.
    2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to Day 1: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours or activated charcoal at a dosage of 50 grams 4 times a day for at least 24 hours.
    3. 24 weeks for cyclophosphamide.
  5. Treatment with any cell-depleting therapies including anti-cluster of differentiation (CD)20 or investigational agents (eg, CAMPATH®, anti-CD4, anti-CD5, anti-CD3, and anti-CD19) with the exception of rituximab. Treatment with rituximab is not allowed within 6 months of Day 1.
  6. Treatment with Tumor necrosis factor alpha inhibitor (TNFi) (including investigational proposed or licensed biosimilars) or any other biologic therapy for the treatment of RA within 12 weeks of Day 1.
  7. Use of parenteral or intra-articular within 4 weeks prior to Day 1.
  8. Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 4 weeks prior to Day 1.
  9. Use of indomethacin and ketorolac; other nonsteroidal anti-inflammatory drugs (NSAIDs) (with the exception of aspirin, see below) must be taken at a stable dose and route of administration for at least 2 weeks prior to Day 1.
  10. Female subjects of nonchildbearing potential taking hormone replacement therapy within 4 weeks prior to Day 1.
  11. Vaccination with in the 6 weeks prior to Day 1 or planned vaccination with live vaccines during the study.
  12. Participation in any other investigational drug study within 30 days or 5 times the t1/2 of the investigational drug, whichever is longer, prior to Day 1.
  13. Use of aspirin or other antiplatelet agents and anticoagulants including warfarin in the 4 weeks prior to Day 1.
  14. Has received any prescription or nonprescription drugs or other products (eg, herbal preparations, food products) known to be inhibitors/inducers of , CYP2C9, CYP2C19, or CYP1A2 within 4 weeks prior to Day 1 and for the duration of the study up to the EOT (Day 29) Visit. The use of MTX, as described in inclusion criterion #5, is permitted.
  15. Use of any herbal preparations (including foods or beverages containing herbal preparations), dietary supplements, or natural medications within 14 days of Day 1.
  16. Has received midazolam and/or omeprazole (or esomeprazole) within 14 days of Day 1.
  17. Excessive intake of caffeine (more than 5 cups of coffee or equivalent per day) and the inability to abstain from caffeine-containing drinks and foods from 2 days prior to each cocktail administration and while inpatient (Day -1 to Day 2 and Day 21 to Day 23, respectively).
  18. Poor metabolizers of CYP2C9 (genotype *2/*2, *2/*3, *3/*3) or CYP2C19 (genotype *2/*2, *2/*3, *3/*3), ultra-rapid metabolizers of CYP2C19 (*17/*17), or high sensitivity to warfarin (VKORCI genotype AA).
  19. Previous participation (enrolled) in this study or another study of OKZ in case of receiving at least one OKZ dose.
  20. Abnormal laboratory values as defined below. If, in the opinion of the Investigator, exclusionary results are due to laboratory error or a transient condition, these tests may be repeated once during Screening.

    a. Creatinine level ≥1.5 mg/dL (132 µmol/L) for females or ≥2.0 mg/dL (177 µmol/L) for males.

    b. (ALT) or Aspartate aminotransferase (AST) level ≥1.5 × .

    c. \<150 × 10\^9/L (\<150,000/mm3).

    d. White blood cell count \<3.0 × 10\^9/L.

    e. \<2.0 × 10\^9/L (\<2000 mm3).

    f. level ≤95 g/L.

    g. Glycosylated hemoglobin () level ≥8%.

    h. above the ULN (Normal range: 0.80 or 0.90 to 1.20, males and females of all ages).

  21. Subjects with concurrent viral or C infection as detected by blood tests at Screening (eg, positive for hepatitis B surface antigen (HBsAg), hepatitis B DNA (HBV DNA) or virus antibody (HCV Ab)).

    1. HBV DNA to be tested only in anti-hepatitis B core antigen (anti-HBc) positive subjects.
    2. Subject who is positive for hepatitis B surface antibody (anti-HBs) and total antiHBc but negative for HBsAg and HBV DNA, will be eligible upon qualified specialist (i.e. hepatologist) consultation with documented conclusion no additional risk is suspected for the subject.
    3. Subject who is positive for hepatitis B surface antibody (anti-HBs) but negative for HBsAg and total anti-HBc, will be eligible with no additional consultation.
  22. Subjects with (HIV) infection.
  23. Subjects with:

    1. Suspected or confirmed current active tuberculosis (TB) disease or a history of active TB disease.
    2. Close contact (ie, sharing the same household or other enclosed environment, such as a social gathering place, workplace or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening.
    3. History of untreated latent TB infection (LTBI), regardless of QuantiFERON-TB Gold Plus interferon-gamma release assay (IGRA) result at Screening.
    4. Positive IGRA result at Screening. If indeterminate, the IGRA can be repeated once during Screening. If there is a second indeterminate result, the subject will be excluded.
  24. Concurrent or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ or successfully treated basal cell carcinoma or squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised nonmelanoma skin cancers within the last 5 years prior to Screening]).
  25. Subjects with a history of major bleeding, bleeding tendencies (such as any prior gastrointestinal bleeding and recent ulceration of gastrointestinal track, congenital and acquired disorders by hemostasis), or other predisposition to bleeding according to the physician's judgment.
  26. Subjects with a history or presence of severe cardiovascular conditions such as stroke, , or myocardial infarction in medical history.
  27. Uncompensated congestive heart failure, or Class III or IV heart failure defined by the classification.
  28. Untreated, uncontrolled, or resistant arterial hypertension Grade 2 to 3 (systolic blood pressure (BP) >160 mm Hg and/or diastolic BP >100 mm Hg, based on the mean of 3 readings). If hypertension is not controlled, subjects should be excluded, and not allowed for rescreening.
  29. Uncontrolled diabetes mellitus (based on the Investigator's judgment).
  30. Subjects with a history or presence of any other cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, hematological, or immunologic/immunodeficiency disorder(s) or any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate subject participation in the clinical study, or clinically significant enough in the opinion of the Investigator to alter the disposition of the study treatment, or constitute a possible confounding factor for assessment of safety of the study treatment..
  31. Subjects with gastrointestinal (GI) resection (eg, partial or total gastrectomy) likely to interfere with absorption of study treatment.
  32. Subjects with any infection requiring any anti-infective therapy (eg, antibiotic, antiviral, or antifungal therapy) in the 4 weeks prior to Day 1, or serious or recurrent infection with history of hospitalization in the 6 months prior to Day 1 or active infection at Day 1.
  33. Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other nonself-limited herpes zoster infections in the 6 months prior to Day 1.
  34. Subjects with planned surgery during the study (up to and including the EOT Visit,[Day 29]) or surgery ≤4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator.
  35. Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (eg, diverticulitis, GI perforation, or ulcerative colitis).
  36. History of chronic alcohol or drug abuse or consumption of more than 21 units (male subjects) or 14 units (female subjects) of alcohol a week (unit = 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer) as judged by the Investigator.
  37. Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to Screening.
  38. Subjects with a known or to any component of the cocktail drugs or OKZ.
  39. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.
  40. Any self-reported symptoms of influenza-like or COVID-19 like illness in the 14 days preceding Screening OR Day 1 as per the Investigators assessment. Symptoms related to COVID-19 include, but are not limited to:

    a. Respiratory symptoms (eg, sore throat, nasal congestion, post-nasal discharge, wheezing, cough, dyspnea, and bronchial breath sounds);

    b. Non-respiratory symptoms, such as gastrointestinal symptoms (eg, nausea, vomiting, and diarrhea), neurologic symptoms (eg, anosmia, ageusia, headache), myalgia or fatigue.

  41. Active SARS-CoV-2 infection as confirmed by reverse transcription polymerase chain reaction (RT-PCR) or/and positive serology at Screening.
  42. Known exposure to an individual with confirmed COVID-19 or SARS-CoV-2 infection within 2 weeks before Screening OR Day 1.
  43. History of COVID-19 infection in the previous 3 months before Day 1 or with sever or critical illness ever.

Note: The subject can be enrolled if all of the following criteria are fulfill:

  1. had non-sever or non-critical COVID-19 infection more than 3 months before Day 1;
  2. fully recovered as per official medical records which should be documented as a source document (mild sequelae of the previous infection such as dry cough, weakness should be resolved by the time of Screening);
  3. there are no any concerns that the subject is infections to others;
  4. there are no any other local guidelines/requirements with regards of this group of subjects.
  1. Those subjects who have been at high risk of exposure before Screening, including but not limited to: Close contacts of confirmed COVID-19 cases, anyone who had to self-isolate as a result of a symptomatic household member, frontline healthcare professionals working in accident and emergency (A\&E), ICU and other higher risk areas.
  1. Individuals currently working with high risk of exposure to SARS-CoV-2 (eg, active healthcare workers or emergency response personnel having direct interactions with or providing direct care to patients).
  1. Pregnancy and breastfeeding.
  1. Other medical or psychiatric conditions or laboratory abnormalities that may increase potential risk associated with study participation and administration of study treatment, or that may affect study results interpretation and, as per the Investigator's judgment.
  1. Subject's unwillingness or inability to follow the procedures outlined in the protocol.
  1. Employees or relatives of the Sponsor, Contract Research Organization, or the study center personnel.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Olokizumab 128 mg +Cocktail drugs

    All subjects have received the following treatment: Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered with 240 mL of water on Day 1, single subcutaneous injection of Olokizumab 128 mg administered on Day 8 and second dose of Cocktail drugs (Omeprazole + Caffeine + Warfarin (+ vitamin K solution) + Midazolam) orally administered on Day 22

    Drug: Olokizumab · Drug: Omeprazole · Drug: Caffeine · Drug: Warfarin+ Vitamin K · Drug: Midazolam

Interventions

  • Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)

  • DrugOmeprazole

    Tablets, 20 mg, oral

  • DrugCaffeine

    Tablets, 100 mg, oral

  • DrugWarfarin+ Vitamin K

    Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.

  • DrugMidazolam

    Syrup, 2 mg/mL, oral

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC(0-inf)) for Caffeine, Omeprazole and Midazolam

    Area under the AUC from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Maximum plasma concentration (Cmax). Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

    Time frame: Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 2), 30 (Day 2, only caffeine) hours post-dose; Day 22: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 23), 30 (Day 23, only caffeine) hours post-dose

  2. AUC From Time Zero to the Time "t" (AUC(0-last)) for S-warfarin

    Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration, calculated by linear up/log down trapezoidal summation for S-warfarin (10 mg warfarin contains 5 mg S-warfarin)

    Time frame: Day 1: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24(Day 2), 48(Day 3), 72 (Day 4), 120 (Day 6), 168 (Day 8) hours post-dose; Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24(Day 23), 48(Day 24), 72 (Day 25), 120 (Day 27), 168 (Day 29) hours post-dose

  3. Maximum Plasma Concentration (Cmax) for All Cocktail Substrates

    Cmax for all cocktail substrates (caffeine, omeprazole, midazolam and S-warfarin), obtained directly from the observed concentration versus time data. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 (only S-warfarin), 72 (only S-warfarin), 120 (only S-warfarin), 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

Secondary outcomes

  1. Plasma AUC(0-last) for Cocktail Parent Compounds (for Caffeine, Omeprazole and Midazolam)

    AUC from time zero to the time of the last quantifiable concentration, calculated by linear up/log down trapezoidal summation for Caffeine, Omeprazole, Midazolam. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

    Time frame: Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 2), 30 (Day 2, only caffeine) hours post-dose; Day 22: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 23), 30 (Day 23, only caffeine) hours post-dose

  2. Plasma AUC From Time Zero to Infinity (AUC(0-inf)) for Cocktail Parent Compounds (for S-warfarin)

    Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation for S-warfarin (10 mg warfarin contains 5 mg S-warfarin).

    Time frame: Day 1: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24, 48, 72, 120, 168 hours post-dose; Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24, 48, 72, 120, 168 hours post-dose

  3. Time to Maximum Plasma Concentration (Tmax) for Cocktail Parent Compounds

    tmax for cocktail parent compounds (caffeine, S-warfarin, omeprazole and midazolam), obtained directly from the observed concentration versus time data.

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 (only S-warfarin), 72 (only S-warfarin), 120 (only S-warfarin), 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

  4. Terminal Half-life (t1/2) for Cocktail Parent Compounds

    Terminal half-life (t1/2) for cocktail parent compounds (caffeine, S-warfarin (10 mg warfarin contains 5 mg S-warfarin), omeprazole, and midazolam)

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

  5. Elimination Rate Constant (λz) for Cocktail Parent Compounds

    elimination rate constant (λz) for cocktail parent compounds (caffeine, S-warfarin (10 mg warfarin contains 5 mg S-warfarin), omeprazole, and midazolam), determined by linear regression of the terminal points of the log-linear concentration-time curve. The Best Fit method utilized by WinNonlin was used to identify the terminal linear phase of the concentration-time profile, with visual assessment and adjustment of the selected data points by the PK scientist if warranted.

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

  6. Apparent Systemic Clearance (CL/F) for Cocktail Parent Compounds

    Apparent systemic clearance (CL/F) for cocktail parent compounds (caffeine, omeprazole, and midazolam), calculated as dose divided by AUC(0-inf). In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

  7. Apparent Volume of Distribution (Vz/F) for Cocktail Parent Compounds

    Vz/F during terminal phase for cocktail parent compounds (caffeine, omeprazole and midazolam), calculated as dose divided by \[λz \*AUC(0-inf)\] In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

    Time frame: Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose

  8. Plasma Concentrations (Cmax) for Olokizumab

    Maximum concentration obtained directly from the observed concentration versus time data for Olokizumab.

    Time frame: Predose: within 30 min of OKZ administration on Day 8; postdose: Day 9, Day 15 (sample collection clock-matched to Day 8 sample), Day 22 (collected prior to administration of DDI cocktail), Day 24, Day 29 (sample collection clock-matched to Day 22 sample)

  9. Change in Interleukin-6 (IL-6) Concentrations Collected Periodically Throughout the Study

    Blood sampling for the measurement of IL-6 were performed at Screening, prior to dosing with the cocktail on Day 1, prior to dose administration with OKZ on Day 8, and post OKZ dose administration on Day 9, Day 15, Day 22 (prior to dose administration of the cocktail on Day 22), and Day 29, which were considered the EOT visit.

    Time frame: Days 1, 8, 9, 15, 22, 29

  10. Change in C-reactive Protein (CRP) Concentrations Collected Periodically Throughout the Study

    Blood sampling for the measurement of CRP were performed at Screening, prior to dosing with the cocktail on Day 1, prior to dose administration with OKZ on Day 8, and post OKZ dose administration on Day 9, Day 15, Day 22 (prior to dose administration of the cocktail on Day 22), and Day 29, which were considered the EOT visit.

    Time frame: Days 1, 8, 9, 15, 22, 29

07

Results

Posted Aug 15, 2024

Participant flow

Enrollment was conducted at 2 sites in 2 countries (Bulgaria and Moldova). A total of 17 subjects were enrolled into Period 1 of the study and 16 subjects each were enrolled into Period 2 and Period 3 of the study. All 17 subjects who received the first dose were enrolled into Safety Analysis Set and 16 subjects were enrolled into Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis Sets.

Period 1: Cocktail Alone
Participant flow — Period 1: Cocktail Alone
MilestoneOlokizumab 128 mg + Cocktail Drugs
Started17
Completed16
Not completed1
Withdrew: Protocol violation1
Period 2: Olokizumab Administration
Participant flow — Period 2: Olokizumab Administration
MilestoneOlokizumab 128 mg + Cocktail Drugs
Started16
Completed16
Not completed0
Period 3: Olokizumab + Cocktail
Participant flow — Period 3: Olokizumab + Cocktail
MilestoneOlokizumab 128 mg + Cocktail Drugs
Started16
Completed16
Not completed0
Safety Follow-up
Participant flow — Safety Follow-up
MilestoneOlokizumab 128 mg + Cocktail Drugs
Started16
Completed16
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC(0-inf)) for Caffeine, Omeprazole and Midazolam

Area under the AUC from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Maximum plasma concentration (Cmax). Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

Time frame:
Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 2), 30 (Day 2, only caffeine) hours post-dose; Day 22: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 23), 30 (Day 23, only caffeine) hours post-dose
Reported as:
Geometric least squares mean · h*ng/mL
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC(0-inf)) for Caffeine, Omeprazole and Midazolam
h*ng/mLOlokizumab 128 mg + Cocktail Drugs
Midazolam38.23 (30.32 to 48.21)
Midazolam + OKZ26.94 (21.43 to 33.86)
Omeprazole1408 (933.5 to 2124)
Omeprazole + OKZ955.8 (635.3 to 1438)
Caffeine (baseline-adjusted)21820 (17610 to 27040)
Caffeine + OKZ (baseline-adjusted)26830 (21580 to 33340)
Statistical analysis
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of auc (0-inf)): 70.46 · 90% CI 60.62 to 81.91Results based on a linear mixed model for the log-transformed values of PK parameters of midazolam with a fixed effect for treatment and a random effect for subject.
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of auc (0-inf)): 67.87 · 90% CI 56.73 to 81.21Results based on a linear mixed model for the log-transformed values of PK parameters of omeprazole with a fixed effect for treatment and a random effect for subject.
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of auc (0-inf)): 122.92 · 90% CI 107.98 to 139.93Results based on a linear mixed model for the log-transformed values of baseline-adjusted PK parameters of caffeine with a with fixed effect for treatment and a random effect for subject.
PrimaryAUC From Time Zero to the Time "t" (AUC(0-last)) for S-warfarin

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration, calculated by linear up/log down trapezoidal summation for S-warfarin (10 mg warfarin contains 5 mg S-warfarin)

Time frame:
Day 1: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24(Day 2), 48(Day 3), 72 (Day 4), 120 (Day 6), 168 (Day 8) hours post-dose; Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24(Day 23), 48(Day 24), 72 (Day 25), 120 (Day 27), 168 (Day 29) hours post-dose
Reported as:
Geometric least squares mean · h*ng/mL
AUC From Time Zero to the Time "t" (AUC(0-last)) for S-warfarin
h*ng/mLOlokizumab 128 mg + Cocktail Drugs
S-Warfarin21350 (18360 to 24820)
S-Warfarin + OKZ19390 (16680 to 22540)
Statistical analysis
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of auc (0-last)): 90.83 · 90% CI 86.72 to 95.13Results based on a linear mixed model for the log-transformed values of PK parameters of S-warfarin with a fixed effect for treatment and a random effect for subject.
PrimaryMaximum Plasma Concentration (Cmax) for All Cocktail Substrates

Cmax for all cocktail substrates (caffeine, omeprazole, midazolam and S-warfarin), obtained directly from the observed concentration versus time data. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 (only S-warfarin), 72 (only S-warfarin), 120 (only S-warfarin), 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Geometric least squares mean · ng/mL
Maximum Plasma Concentration (Cmax) for All Cocktail Substrates
ng/mLOlokizumab 128 mg + Cocktail Drugs
Midazolam13.29 (11.08 to 15.93)
Midazolam + OKZ9.101 (7.593 to 10.91)
Omeprazole668.6 (522.4 to 855.6)
Omeprazole + OKZ491.7 (385.2 to 627.7)
Caffeine (baseline adjusted)2803 (2570 to 3057)
Caffeine + OKZ (baseline adjusted)2746 (2523 to 2990)
S-Warfarin627.0 (571.5 to 688.0)
S-Warfarin + OKZ641.5 (584.6 to 703.9)
Statistical analysis
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of cmax: 68.50 · 90% CI 59.46 to 78.92Results based on a linear mixed model for the log-transformed values of PK parameters of midazolam with a fixed effect for treatment and a random effect for subject.
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of cmax: 73.54 · 90% CI 64.18 to 84.27Results based on a linear mixed model for the log-transformed values of PK parameters of omeprazole with a fixed effect for treatment and a random effect for subject.
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of cmax: 97.99 · 90% CI 91.36 to 105.09Results based on a linear mixed model for the log-transformed values of baseline-adjusted PK parameters of caffeine with a with fixed effect for treatment and a random effect for subject.
  • Olokizumab 128 mg + Cocktail Drugs · Geometric ls mean ratio of cmax: 102.30 · 90% CI 94.80 to 110.39Results based on a linear mixed model for the log-transformed values of PK parameters of S-warfarin with a fixed effect for treatment and a random effect for subject.
SecondaryPlasma AUC(0-last) for Cocktail Parent Compounds (for Caffeine, Omeprazole and Midazolam)

AUC from time zero to the time of the last quantifiable concentration, calculated by linear up/log down trapezoidal summation for Caffeine, Omeprazole, Midazolam. In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

Time frame:
Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 2), 30 (Day 2, only caffeine) hours post-dose; Day 22: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24 (Day 23), 30 (Day 23, only caffeine) hours post-dose
Reported as:
Geometric mean · h*ng/mL
Plasma AUC(0-last) for Cocktail Parent Compounds (for Caffeine, Omeprazole and Midazolam)
h*ng/mLOlokizumab 128 mg + Cocktail Drugs
Midazolam36.77 ± 43.0
Midazolam + OKZ24.73 ± 49.6
Omeprazole1461 ± 92.2
Omeprazole + OKZ951.1 ± 86.3
Caffeine (baseline-adjusted)21860 ± 42.2
Caffeine (baseline-adjusted) + OKZ26910 ± 42.8
SecondaryPlasma AUC From Time Zero to Infinity (AUC(0-inf)) for Cocktail Parent Compounds (for S-warfarin)

Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation for S-warfarin (10 mg warfarin contains 5 mg S-warfarin).

Time frame:
Day 1: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24, 48, 72, 120, 168 hours post-dose; Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 7, 12, 24, 48, 72, 120, 168 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Plasma AUC From Time Zero to Infinity (AUC(0-inf)) for Cocktail Parent Compounds (for S-warfarin)
h*ng/mLOlokizumab 128 mg + Cocktail Drugs
S-warfarin21350 ± 29.4
S-warfarin + OKZ19390 ± 28.7
SecondaryTime to Maximum Plasma Concentration (Tmax) for Cocktail Parent Compounds

tmax for cocktail parent compounds (caffeine, S-warfarin, omeprazole and midazolam), obtained directly from the observed concentration versus time data.

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 (only S-warfarin), 72 (only S-warfarin), 120 (only S-warfarin), 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) for Cocktail Parent Compounds
hoursOlokizumab 128 mg + Cocktail Drugs
Midazolam0.500 (0.48 to 1.03)
Midazolam + OKZ0.533 (0.50 to 1.03)
Omeprazole2.000 (1.00 to 3.03)
Omeprazole + OKZ2.000 (1.00 to 4.03)
Caffeine (baseline-adjusted)0.533 (0.23 to 2.00)
Caffeine (baseline-adjusted) + OKZ0.558 (0.50 to 2.03)
S-Warfarin1.500 (0.50 to 3.03)
S-Warfarin + OKZ1.500 (0.25 to 4.00)
SecondaryTerminal Half-life (t1/2) for Cocktail Parent Compounds

Terminal half-life (t1/2) for cocktail parent compounds (caffeine, S-warfarin (10 mg warfarin contains 5 mg S-warfarin), omeprazole, and midazolam)

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Geometric mean · hours
Terminal Half-life (t1/2) for Cocktail Parent Compounds
hoursOlokizumab 128 mg + Cocktail Drugs
Midazolam6.726 ± 28.6
Midazolam + OKZ6.520 ± 32.8
Omeprazole1.279 ± 59.8
Omeprazole + OKZ0.9859 ± 51.5
Caffeine (baseline-adjusted)6.375 ± 43.1
Caffeine (baseline-adjusted) + OKZ8.046 ± 48.2
S-Warfarin43.94 ± 13.6
S-Warfarin + OKZ38.57 ± 14.6
SecondaryElimination Rate Constant (λz) for Cocktail Parent Compounds

elimination rate constant (λz) for cocktail parent compounds (caffeine, S-warfarin (10 mg warfarin contains 5 mg S-warfarin), omeprazole, and midazolam), determined by linear regression of the terminal points of the log-linear concentration-time curve. The Best Fit method utilized by WinNonlin was used to identify the terminal linear phase of the concentration-time profile, with visual assessment and adjustment of the selected data points by the PK scientist if warranted.

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Geometric mean · 1/hours
Elimination Rate Constant (λz) for Cocktail Parent Compounds
1/hoursOlokizumab 128 mg + Cocktail Drugs
Midazolam0.1031 ± 28.6
Midazolam + OKZ0.1063 ± 32.8
Omeprazole0.5418 ± 59.8
Omeprazole + OKZ0.7031 ± 51.5
Caffeine (baseline-adjusted)0.1087 ± 43.1
Caffeine (baseline-adjusted) + OKZ0.08615 ± 48.2
S-Warfarin0.01578 ± 13.6
S-Warfarin + OKZ0.01797 ± 14.6
SecondaryApparent Systemic Clearance (CL/F) for Cocktail Parent Compounds

Apparent systemic clearance (CL/F) for cocktail parent compounds (caffeine, omeprazole, and midazolam), calculated as dose divided by AUC(0-inf). In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Geometric mean · L/hours
Apparent Systemic Clearance (CL/F) for Cocktail Parent Compounds
L/hoursOlokizumab 128 mg + Cocktail Drugs
Midazolam53.23 ± 41.4
Midazolam + OKZ74.24 ± 50.2
Omeprazole13.58 ± 94.3
Omeprazole + OKZ20.93 ± 86.9
Caffeine (baseline-adjusted)4.582 ± 37.9
Caffeine (baseline-adjusted) + OKZ3.805 ± 40.9
SecondaryApparent Volume of Distribution (Vz/F) for Cocktail Parent Compounds

Vz/F during terminal phase for cocktail parent compounds (caffeine, omeprazole and midazolam), calculated as dose divided by \[λz \*AUC(0-inf)\] In case of anomalous predose concentration of greater than 5% of Cmax was indicated, the PK parameters for the affected analyte and given subject were excluded from the analyses. Since caffeine is contained in the plethora of foods and beverages, most subjects had predose caffeine concentrations on Day 1 and Day 22 that exceeded 5% of their Cmax. Caffeine PK parameter calculations and analyses were performed using concentrations adjusted by subtracting the contribution of the predose caffeine levels at each postdose timepoint using the following equation: Concentration (adjusted) = Concentration (observed) - \[C predose \* exp(-k\*t)\], with 'k' representing the patient-specific elimination rate constant (λz) determined using observed caffeine concentration data on Day 1 and Day 22 and 't' representing the actual time postdose.

Time frame:
Day 1: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose; Day 22: pre-dose, 0.5 - 24, 30 (only caffeine), 48 - 168 (only S-warfarin) hours post-dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution (Vz/F) for Cocktail Parent Compounds
LOlokizumab 128 mg + Cocktail Drugs
Midazolam492.6 ± 35.4
Midazolam + OKZ698.3 ± 43.3
Omeprazole25.06 ± 31.4
Omeprazole + OKZ29.76 ± 33.4
Caffeine (baseline-adjusted)38.86 ± 19.9
Caffeine (baseline-adjusted) + OKZ37.70 ± 37.70
SecondaryPlasma Concentrations (Cmax) for Olokizumab

Maximum concentration obtained directly from the observed concentration versus time data for Olokizumab.

Time frame:
Predose: within 30 min of OKZ administration on Day 8; postdose: Day 9, Day 15 (sample collection clock-matched to Day 8 sample), Day 22 (collected prior to administration of DDI cocktail), Day 24, Day 29 (sample collection clock-matched to Day 22 sample)
Reported as:
Median · ng/mL
Plasma Concentrations (Cmax) for Olokizumab
ng/mLOlokizumab 128 mg + Cocktail Drugs
Plasma Concentrations (Cmax) for Olokizumab15670 (5030 to 24100)
SecondaryChange in Interleukin-6 (IL-6) Concentrations Collected Periodically Throughout the Study

Blood sampling for the measurement of IL-6 were performed at Screening, prior to dosing with the cocktail on Day 1, prior to dose administration with OKZ on Day 8, and post OKZ dose administration on Day 9, Day 15, Day 22 (prior to dose administration of the cocktail on Day 22), and Day 29, which were considered the EOT visit.

Time frame:
Days 1, 8, 9, 15, 22, 29
Reported as:
Mean · pg/mL
Change in Interleukin-6 (IL-6) Concentrations Collected Periodically Throughout the Study
pg/mLOlokizumab 128 mg + Cocktail Drugs
Baseline26.224 ± 35.0576
Day 816.414 ± 20.2591
Change from Baseline on Day 8-9.810 ± 34.8049
Day 92.518 ± 1.2827
Change from Baseline on Day 9-23.706 ± 35.4123
Day 156.434 ± 6.7420
Change from Baseline on Day 15-19.790 ± 35.0774
Day 226.796 ± 7.5603
Change from Baseline on Day 22-19.429 ± 35.4360
Day 295.699 ± 4.8192
Change from Baseline on Day 29-20.526 ± 34.8727
SecondaryChange in C-reactive Protein (CRP) Concentrations Collected Periodically Throughout the Study

Blood sampling for the measurement of CRP were performed at Screening, prior to dosing with the cocktail on Day 1, prior to dose administration with OKZ on Day 8, and post OKZ dose administration on Day 9, Day 15, Day 22 (prior to dose administration of the cocktail on Day 22), and Day 29, which were considered the EOT visit.

Time frame:
Days 1, 8, 9, 15, 22, 29
Reported as:
Mean · mg/L
Change in C-reactive Protein (CRP) Concentrations Collected Periodically Throughout the Study
mg/LOlokizumab 128 mg + Cocktail Drugs
Baseline22.969 ± 33.9274
Day 815.153 ± 15.3990
Change from Baseline on Day 8-7.817 ± 26.8275
Day 911.783 ± 11.5188
Change from Baseline on Day 9-11.187 ± 29.3898
Day 152.266 ± 2.0937
Change from Baseline on Day 15-20.703 ± 34.3184
Day 222.044 ± 2.5411
Change from Baseline on Day 22-20.926 ± 34.5988
Day 292.312 ± 2.8719
Change from Baseline on Day 29-20.657 ± 34.8682

Adverse events

Collected over From the signing of the Informed Consent Form (ICF) until the final end of study (EOS) telephonic follow-up visit (Day 161 ±10 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olokizumab 128 mg + Cocktail Drugs0/17 (0%)0/17 (0%)6/17 (35.3%)
Most frequent other events
Most frequent other events
EventOlokizumab 128 mg + Cocktail Drugs
AnaemiaBlood and lymphatic system disorders2/17
Urinary Tract InfectionInfections and infestations2/17
NauseaGastrointestinal disorders1/17
Drug-Induced Liver InjuryHepatobiliary disorders1/17
Blood Cholesterol IncreasedInvestigations1/17
Lymphocyte Count DecreasedInvestigations1/17
White Blood Cell Count DecreasedInvestigations1/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Olokizumab 128 mg + Cocktail Drugs
Mean51.1 (27 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Olokizumab 128 mg + Cocktail Drugs
Female11
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olokizumab 128 mg + Cocktail Drugs
Hispanic or Latino0
Not Hispanic or Latino17
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olokizumab 128 mg + Cocktail Drugs
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White17
More than one race0
Unknown or Not Reported0
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Olokizumab 128 mg + Cocktail Drugs
Mean27.58 (23.8 to 29.8)
C-reactive protein (CRP)
C-reactive protein (CRP)(mg/L)Olokizumab 128 mg + Cocktail Drugs
Mean21.996 ± 33.0943
08

Study locations

2 sites
  • Comac Medical Ltd
    Sofia, 1618, Bulgaria
  • ICS ARENSIA Exploratory Medicine SRL, a daughter company of ARENSIA Exploratory Medicine GmbH,Republican Clinical Hospital
    Chisinau, MD2025, Moldova, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jun 2022, 6 months.

Results were first posted in Aug 2024, 2 years 2 months after primary completion.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 6 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 29, 2020
StartActual
Nov 16, 2021
Primary completionActual
Jun 8, 2022
CompletionActual
Oct 26, 2022
Results first posted
Aug 15, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04246762
Collaborators
IQVIA Pvt. Ltd, Thermo Fisher Scientific FS
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Nov 16, 2021
Primary completion
Jun 8, 2022
Completion
Oct 26, 2022
Results posted
Aug 15, 2024
Last update
Aug 15, 2024

Study contacts

Mikhail Samsonov
study director · Chief Medical Officer, R-Pharm

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion